drugset / Trial / NCT02765724
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects
Non-randomizedParallel-groupOpen-labelOther
Summary
This is an open-label, parallel-group, single-dose study of the PK and safety of 400 mg pacritinib administered orally to patients with stable chronic liver disease and healthy control subjects.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacritinib | Small molecule | 400 mg | Oral |